A detailed history of Times Square Capital Management, LLC transactions in Legend Biotech Corp stock. As of the latest transaction made, Times Square Capital Management, LLC holds 1,173,766 shares of LEGN stock, worth $59.6 Million. This represents 0.83% of its overall portfolio holdings.

Number of Shares
1,173,766
Previous 1,158,500 1.32%
Holding current value
$59.6 Million
Previous $65 Million 20.0%
% of portfolio
0.83%
Previous 0.94%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$39.5 - $57.22 $603,007 - $873,520
15,266 Added 1.32%
1,173,766 $52 Million
Q1 2024

May 07, 2024

BUY
$55.06 - $69.99 $5.1 Million - $6.48 Million
92,611 Added 8.69%
1,158,500 $65 Million
Q4 2023

Feb 07, 2024

BUY
$57.25 - $69.74 $8.14 Million - $9.91 Million
142,118 Added 15.38%
1,065,889 $64.1 Million
Q3 2023

Nov 17, 2023

BUY
$63.16 - $76.5 $301,841 - $365,593
4,779 Added 0.52%
923,771 $62.1 Million
Q2 2023

Aug 09, 2023

SELL
$46.28 - $75.01 $6.69 Million - $10.8 Million
-144,618 Reduced 13.6%
918,992 $63.4 Million
Q1 2023

May 10, 2023

BUY
$43.42 - $57.37 $5.08 Million - $6.72 Million
117,110 Added 12.37%
1,063,610 $51.3 Million
Q4 2022

Feb 10, 2023

BUY
$38.8 - $55.46 $201,759 - $288,392
5,200 Added 0.55%
946,500 $47.2 Million
Q3 2022

Nov 09, 2022

BUY
$38.15 - $57.1 $32.4 Million - $48.5 Million
849,800 Added 928.74%
941,300 $38.4 Million
Q2 2022

Aug 05, 2022

BUY
$33.54 - $55.0 $184,470 - $302,500
5,500 Added 6.4%
91,500 $5.03 Million
Q1 2022

May 06, 2022

BUY
$31.02 - $48.18 $2.67 Million - $4.14 Million
86,000 New
86,000 $3.13 Million
Q3 2020

Nov 06, 2020

SELL
$27.5 - $39.61 $3.69 Million - $5.31 Million
-134,100 Closed
0 $0
Q2 2020

Aug 07, 2020

BUY
$36.1 - $42.56 $4.84 Million - $5.71 Million
134,100 New
134,100 $5.71 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $8.5B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Times Square Capital Management, LLC Portfolio

Follow Times Square Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Times Square Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Times Square Capital Management, LLC with notifications on news.